Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

25
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
25
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

2.2K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.2K
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

25
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
25
Cross-bridge Cycle01:26

Cross-bridge Cycle

108.7K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
108.7K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

2.2K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Psychometric Properties of the Myotonic Dystrophy Health Index in a Large Multicenter Cohort of People Living With Myotonic Dystrophy Type 1.

Muscle & nerve·2026
Same author

Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1.

Neurology·2026
Same author

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

The New England journal of medicine·2026
Same author

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study.

PloS one·2025
Same author

Elimination of myotonia improves myopathy in a muscleblind knockout model of myotonic dystrophy.

bioRxiv : the preprint server for biology·2025
Same author

Study of Testosterone and Recombinant Human Growth Hormone in Facioscapulohumeral Muscular Dystrophy.

Neurology. Genetics·2025
Same journal

Sports Neurology.

Neurologic clinics·2026
Same journal

Sports-Related Peripheral Nerve Injuries.

Neurologic clinics·2026
Same journal

Active Rehabilitation and Return to Play in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Autonomic Assessment and Management in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Management of Vestibular Symptoms in Sports-Related Concussion.

Neurologic clinics·2026
Same journal

Neuropsychological Assessment in Sport-Related Concussion: Evidence, Controversies, and Clinical Applications.

Neurologic clinics·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

14.9K

Myotonic dystrophy.

Charles A Thornton1

  • 1Department of Neurology, Center for Neural Development and Disease, Center for RNA Biology, University of Rochester Medical Center, Box 645, 601 Elmwood Avenue, Rochester, NY 14642, USA.

Neurologic Clinics
|July 20, 2014
PubMed
Summary
This summary is machine-generated.

Myotonic dystrophy (DM) is a common genetic disorder affecting multiple systems. This review covers DM types 1 and 2, their clinical features, and potential targeted therapies.

Keywords:
ElectrophysiologyExpanded DNA repeatMyopathyMyotonic dystrophy

More Related Videos

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.9K
Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

8.5K

Related Experiment Videos

Last Updated: Apr 26, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

14.9K
Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies
14:10

Isometric and Eccentric Force Generation Assessment of Skeletal Muscles Isolated from Murine Models of Muscular Dystrophies

Published on: January 31, 2013

33.9K
Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

8.5K

Area of Science:

  • Genetics and Molecular Biology
  • Neurology
  • Rare Diseases

Background:

  • Myotonic dystrophy (DM) comprises two distinct genetic disorders, DM type 1 and DM type 2.
  • Both forms exhibit autosomal dominant inheritance and affect multiple organ systems.
  • Common features include myotonic myopathy, cataracts, and cardiac conduction abnormalities.

Purpose of the Study:

  • To review the clinical presentation and pathophysiology of myotonic dystrophy.
  • To discuss current management strategies for DM.
  • To explore future therapeutic targets for DM.

Main Methods:

  • Literature review of clinical studies and research articles on myotonic dystrophy.
  • Synthesis of information on genetic basis, clinical manifestations, and disease mechanisms.
  • Analysis of current treatment approaches and emerging therapeutic avenues.

Main Results:

  • Myotonic dystrophy is a significant inherited disorder with multisystemic impact.
  • DM type 1 and type 2 share clinical features but arise from different genetic mutations.
  • Current management focuses on symptom control, while targeted therapies are under development.

Conclusions:

  • Myotonic dystrophy necessitates comprehensive management due to its multisystemic nature.
  • Understanding the pathophysiology is key to developing effective treatments.
  • Future research holds promise for targeted therapies to improve patient outcomes.